Retrovirus-mediated gene therapy for human hepatocellular carcinoma transplanted in athymic mice

Int J Mol Med. 1998 Apr;1(4):671-5. doi: 10.3892/ijmm.1.4.671.

Abstract

Gene therapy using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of the 0.3-kb human alpha-fetoprotein (AFP) gene promoter (LNAF0.3TK virus) in combination with ganciclovir (GCV) treatment was performed in athymic mice harboring AFP-producing HuH-7 human hepatoma cells. GCV treatment resulted in pronounced growth inhibition of the virus-infected HuH-7 xenograft in mice, but did not affect growth of the parental xenograft. These results indicate that the AFP gene promoter sequence allows enough therapeutic gene expression to induce the GCV-mediated cytotoxicity in vivo in AFP-producing human hepatoma cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / therapy*
  • Carcinoma, Hepatocellular / virology
  • Ganciclovir / pharmacology
  • Genetic Therapy / methods*
  • Genetic Vectors / pharmacology*
  • Humans
  • Liver Neoplasms, Experimental / therapy*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neoplasm Transplantation
  • Retroviridae / genetics*
  • Thymidine Kinase / genetics
  • Tumor Cells, Cultured
  • alpha-Fetoproteins / analysis
  • alpha-Fetoproteins / drug effects
  • alpha-Fetoproteins / genetics

Substances

  • alpha-Fetoproteins
  • Thymidine Kinase
  • Ganciclovir